Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degeneration

1 Dec 2019

Abstract excerpt

OBJECTIVE: Age-related macular degeneration (ARMD) is a leading cause of visual impairment. Intravitreal injections of anti-vascular endothelial growth factor (VEGF) are the standard treatment for wet ARMD. There is however, variability in patient responses, suggesting patient-specific factors influencing drug efficacy. We tested whether single nucleotide polymorphisms (SNPs) in genes encoding VEGF pathway...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ophthalmology and Visual Impairment Studies
Share to Retinal Development and Disorders
Share to Retinal Diseases and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31909188
DOI: 10.1136/bmjophth-2019-000273

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degenerationPMID 31909188Read ↗

Genetics in neovascular age-related macular degeneration susceptibility and treatment response to anti-VEGF intravitreal injection: A case series study.Semantic proximity Read ↗

Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration.Semantic proximity Read ↗

Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.Semantic proximity Read ↗

Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.Semantic proximity Read ↗

VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).Semantic proximity Read ↗

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.Semantic proximity Read ↗

Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Common variant in VEGFA and response to anti-VEGF therapy for neovascular age-related macular degeneration.Semantic proximity Read ↗

Predictors of anti-VEGF treatment response in neovascular age-related macular degenerationSemantic proximity Read ↗

Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.Semantic proximity Read ↗

Genetic markers of the effectiveness of anti-VEGF therapy in age-related macular degenerationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.